-
公开(公告)号：US20210260353A1
公开(公告)日：2021-08-26
申请号：US17244324
申请日：2021-04-29
申请人： MuPharma Pty Ltd
发明人： Harry Unger , Mark Unger , Sean Michael Langelier
摘要： There is disclosed systems and methods for non-invasive delivery of an agent to biological tissues. Delivery of the agent to the tissues can be by one or more modalities. In some embodiments the systems and methods use agent carrier body including a tissue contacting surface for non-invasively engaging tissues under treatment. The tissue contacting surface can be at least partly defined by a plurality of protrusions that are in fluid communication with one or more reservoirs forming part of the agent carrier body. The protrusions may extend outward from an inside of a void and terminate at said tissue contacting surface.
-
公开(公告)号：US20170312490A1
公开(公告)日：2017-11-02
申请号：US15592380
申请日：2017-05-11
申请人： MuPharma Pty Ltd
发明人： Harry Unger , Mark Unger , Sean Michael Langelier
CPC分类号： A61M37/0092 , A61K39/12 , A61K39/21 , A61K41/0047 , A61K2039/5256 , A61K2039/54 , A61M37/0015 , A61M2037/0007 , A61M2037/0023 , A61M2205/3344 , A61M2205/3375 , A61N1/30 , A61N7/00 , C12N7/00 , C12N2710/24021 , C12N2710/24043 , C12N2710/24143 , C12N2740/16034 , C12N2740/16071
摘要： There is disclosed systems and methods for non-invasive delivery of an agent to biological tissues. Delivery of the agent to the tissues can be by one or more modalities. In some embodiments the systems and methods use agent carrier body including a tissue contacting surface for non-invasively engaging tissues under treatment. The tissue contacting surface can be at least partly defined by a plurality of protrusions that are in fluid communication with one or more reservoirs forming part of the agent carrier body. The protrusions may extend outward from an inside of a void and terminate at said tissue contacting surface.
-
公开(公告)号：US12115333B2
公开(公告)日：2024-10-15
申请号：US17244324
申请日：2021-04-29
申请人： MuPharma Pty Ltd
发明人： Harry Unger , Mark Unger , Sean Michael Langelier
CPC分类号： A61M37/0092 , A61K39/12 , A61K39/21 , A61K41/0047 , A61M37/0015 , A61N1/30 , A61N7/00 , C12N7/00 , A61K2039/5256 , A61K2039/54 , A61M2037/0007 , A61M2037/0023 , A61M2205/3344 , A61M2205/3375 , C12N2710/24021 , C12N2710/24043 , C12N2710/24143 , C12N2740/16034 , C12N2740/16071
摘要： There is disclosed systems and methods for non-invasive delivery of an agent to biological tissues. Delivery of the agent to the tissues can be by one or more modalities. In some embodiments the systems and methods use agent carrier body including a tissue contacting surface for non-invasively engaging tissues under treatment. The tissue contacting surface can be at least partly defined by a plurality of protrusions that are in fluid communication with one or more reservoirs forming part of the agent carrier body. The protrusions may extend outward from an inside of a void and terminate at said tissue contacting surface.
-
公开(公告)号：US20160101273A1
公开(公告)日：2016-04-14
申请号：US14889800
申请日：2014-05-06
申请人： MuPharma Pty Ltd
发明人： Harry Unger , Sean Michael Langelier , Mark Unger
IPC分类号： A61M37/00
CPC分类号： A61M37/0092 , A61M2037/0007 , A61M2037/0023 , A61M2037/003 , A61M2037/0053 , A61N1/30
摘要： An agent carrier delivers an agent to biological tissues by one or more modalities. The modality of delivery may be one or more transportation stimulus that causes the agent to be transported through the agent carrier. The transportation stimulus also enhances or permits penetration of the agent into the tissue. The agent carrier has an agent carrier body that is configured to retain the agent within the agent carrier body. The agent carrier body has a tissue-contacting surface for engaging tissues under treatment. Application of the transportation stimulus causes transportation of the agent through the agent carrier body to the tissue-contacting surface.
摘要翻译： 药剂载体通过一种或多种方式将药剂递送至生物组织。 递送的方式可以是一种或多种运输刺激，其导致药剂通过药剂载体运输。 运输刺激也增强或允许药剂渗透到组织中。 试剂载体具有构造成将试剂保持在试剂载体内部的试剂载体主体。 药剂载体具有用于接合处理组织的组织接触表面。 运输刺激的应用导致药剂通过药剂载体运送到组织接触表面。
-
公开(公告)号：US12029873B2
公开(公告)日：2024-07-09
申请号：US16939796
申请日：2020-07-27
申请人： MuPharma Pty Ltd
发明人： Harry Unger , Sean Michael Langelier , Mark Unger
CPC分类号： A61M37/0092 , A61M37/00 , A61N1/0448 , A61N1/303 , A61M2037/0007 , A61M2037/0023 , A61M2037/003
摘要： There is disclosed systems and methods for non-invasive delivery of an agent to biological tissues. Delivery of the agent to the tissues can be by one or more modalities. In some embodiments the systems and methods use agent carrier body including a tissue contacting surface for non-invasively engaging tissues under treatment. The tissue contacting surface can be at least partly defined by a plurality of protrusions that are in fluid communication with one or more reservoirs forming part of the agent carrier body. The protrusions may extend outward from an inside of a void and terminate at said tissue contacting surface.
-
公开(公告)号：US20240216661A1
公开(公告)日：2024-07-04
申请号：US18608706
申请日：2024-03-18
申请人： MuPharma Pty Ltd
发明人： Harry Unger , Sean Michael Langelier , Mark Unger
CPC分类号： A61M37/0092 , A61M37/00 , A61N1/0448 , A61N1/303 , A61M2037/0007 , A61M2037/0023 , A61M2037/003
摘要： There is disclosed systems and methods for non-invasive delivery of an agent to biological tissues. Delivery of the agent to the tissues can be by one or more modalities. In some embodiments the systems and methods use agent carrier body including a tissue contacting surface for non-invasively engaging tissues under treatment. The tissue contacting surface can be at least partly defined by a plurality of protrusions that are in fluid communication with one or more reservoirs forming part of the agent carrier body. The protrusions may extend outward from an inside of a void and terminate at said tissue contacting surface.
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.014 秒)
